Nalorphine (INN) (brand names Lethidrone, Nalline), also known as N-allylnormorphine, is a mixed opioidagonist–antagonist with opioid antagonist and analgesic properties.[1] It was introduced in 1954[2] and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence.[3]
Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963.[2] Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.[1][2][4]
Nalorphine acts at two opioid receptors — the μ-opioid receptor (MOR) where it has antagonistic effects, and at the κ-opioid receptor (KOR) (Ki = 1.6 nM; EC50 = 483 nM; Emax = 95%) where it exerts high-efficacypartial agonist/near-full agonist characteristics.[5]
Chemistry[]
Analogues[]
Nalorphine has a number of analogues including niconalorphine (the nicomorphine analogue), diacetylnalorphine (heroin analogue), (dihydromorphine), and a number of others as well as a number of codeine-based analogues.[6]
More recently, it has become much more commonplace to use ethyl chloroformate instead of cyanogen bromide for the Von Braun degradation demethylation step. See for example the list of phenyltropanes or the synthesis of paroxetine for further examples of this.
See also[]
Diacetylnalorphine
Levallorphan
Nalbuphine
Nalorphine dinicotinate
References[]
^ abGlatt M (6 December 2012). The Dependence Phenomenon. Springer Science & Business Media. pp. 121–. ISBN978-94-011-7457-2.
^Satoskar RS, Rege N, Bhandarkar SD (27 July 2015). Pharmacology and Pharmacotherapeutics. Elsevier Health Sciences APAC. pp. 166–. ISBN978-81-312-4371-8.
^McCawley EL, Hart ER, Marsh DF (January 1941). "The preparation of N-allylnormorphine". Journal of the American Chemical Society. 63 (1): 314. doi:10.1021/ja01846a504.
^Weijlard J, Erickson AE (1942). "N-Allylnormorphine". Journal of the American Chemical Society. 64 (4): 869–870. doi:10.1021/ja01256a036.
Salvinorin A Also indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).